Oncolytics Biotech Marge EBITDA

Que fait Oncolytics Biotech ? Oncolytics Biotech Inc. develops pelareorep, an intravenously delivered immunotherapeutic agent targeting gastrointestinal tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. The company generates revenue through research and development agreements, including a supply agreement with Roche Holding AG for atezolizumab, which is used in its sponsored studies. Oncolytics focuses on clinical-stage oncology treatments, leveraging partnerships to advance its pipeline without commercializing products yet. Roche Holding AG supplies atezolizumab under an agreement with Oncolytics, enabling the company to conduct studies on pelareorep in combination with immune checkpoint inhibitors. This collaboration supports Oncolytics' research efforts in oncology, particularly for GI tumor treatments and metastatic cancers. The company remains in the clinical development phase, with no current commercial products. Oncolytics Biotech Inc. operates as a clinical-stage biopharmaceutical company, concentrating on immunotherapeutic agents for specific cancer types. Its primary revenue stream comes from research partnerships, such as the Roche collaboration, rather than product sales. The company does not yet have commercialized treatments, relying instead on sponsored studies and development agreements to fund its operations. Oncolytics Biotech est l'une des entreprises les plus populaires sur Eulerpool.